A Herpesvirus saimiri-based vector expressing TRAIL induces cell death in human carcinoma cell lines and multicellular spheroid cultures

被引:3
作者
Turrell, Susan J. [1 ,2 ]
Macnab, Stuart A. [1 ,2 ]
Rose, Ailsa [3 ]
Melcher, Alan A. [3 ]
Whitehouse, Adrian [1 ,2 ]
机构
[1] Univ Leeds, Fac Biol Sci, Inst Mol & Cellular Biol, Leeds LS2 9JT, W Yorkshire, England
[2] Univ Leeds, Astbury Ctr Struct Mol Biol, Leeds LS2 9JT, W Yorkshire, England
[3] St James Univ Hosp, Leeds Inst Mol Med, Canc Res UK, Leeds LS9 7TF, W Yorkshire, England
基金
英国生物技术与生命科学研究理事会;
关键词
Herpesvirus saimiri; TRAIL; gene therapy; GENE DELIVERY VECTOR; PANCREATIC-CANCER CELLS; OPEN READING FRAME-73; INDUCED APOPTOSIS; EPISOMAL PERSISTENCE; THYMIDINE KINASE; HUMAN SURVIVIN; T-CELLS; INHIBITOR; MECHANISMS;
D O I
10.3892/ijo.2012.1394
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Herpesvirus saimiri (HVS) is capable of infecting a range of human carcinoma cell types with high efficiency and the viral genome persists as high copy number, circular, non-integrated episomes which segregate to progeny upon cell division. This allows HVS-based vectors to stably transduce a dividing cell population and provide sustained transgene expression for an extended period of time both in vitro and in vivo. Moreover, the insertion of a bacterial artificial chromosome cassette into the HVS genome simplifies the incorporation of large amounts of heterologous DNA for gene delivery. Herein we have produced a recombinant HVS-based vector containing full-length human TRAIL under the control of the a-survivin promoter, and subsequently challenged a variety of cancer cell lines with this vector. The TRAIL transgene was expressed in infected colorectal SW480 cells, causing considerable apoptosis induction. Apoptosis was also observed when several other cancer cell lines derived from different tissues were infected. Moreover, co-treatment with Jak inhibitor AG490 led to the disruption of spheroid cultures grown from the melanoma Mel888 line. These data suggest that an H VS gene therapy vector expressing TRAIL could be an effective treatment against cancer.
引用
收藏
页码:2081 / 2089
页数:9
相关论文
共 46 条
[1]   A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma [J].
Ambrosini, G ;
Adida, C ;
Altieri, DC .
NATURE MEDICINE, 1997, 3 (08) :917-921
[2]   Bortezomib Sensitizes Human Renal Cell Carcinomas to TRAIL Apoptosis through Increased Activation of Caspase-8 in the Death-Inducing Signaling Complex [J].
Brooks, Alan D. ;
Jacobsen, Kristen M. ;
Li, Wenqing ;
Shanker, Anil ;
Sayers, Thomas J. .
MOLECULAR CANCER RESEARCH, 2010, 8 (05) :729-738
[3]   Open reading frame 73 is required for herpesvirus saimiri A11-S4 episomal persistence [J].
Calderwood, M ;
White, RE ;
Griffiths, RA ;
Whitehouse, A .
JOURNAL OF GENERAL VIROLOGY, 2005, 86 :2703-2708
[4]   The herpesvirus saimiri ORF73 gene product interacts with host-cell mitotic chromosomes and self-associates via its C terminus [J].
Calderwood, MA ;
Hall, KT ;
Matthews, DA ;
Whitehouse, A .
JOURNAL OF GENERAL VIROLOGY, 2004, 85 :147-153
[5]  
Calderwood NA, 2004, EXPERT OPIN BIOL TH, V4, P493
[6]   SYNTHESIS OF BOVINE GROWTH-HORMONE IN PRIMATES BY USING A HERPESVIRUS VECTOR [J].
DESROSIERS, RC ;
KAMINE, J ;
BAKKER, A ;
SILVA, D ;
WOYCHIK, RP ;
SAKAI, DD ;
ROTTMAN, FM .
MOLECULAR AND CELLULAR BIOLOGY, 1985, 5 (10) :2796-2803
[7]  
FALK LA, 1972, JNCI-J NATL CANCER I, V48, P1499
[8]   Jak inhibitor induces S phase cell-cycle arrest and augments TRAM-induced apoptosis in human hepatocellular carcinoma cells [J].
Fuke, Hiroyuki ;
Shiraki, Katsuya ;
Sugimoto, Kazushi ;
Tanaka, Junichiro ;
Beppu, Tetsuya ;
Yoneda, Kentaro ;
Yamamoto, Norihiko ;
Ito, Keiichi ;
Masuya, Masahiro ;
Takei, Yoshlyuki .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2007, 363 (03) :738-744
[9]   SELECTABLE RECOMBINANT HERPESVIRUS SAIMIRI IS CAPABLE OF PERSISTING IN A HUMAN T-CELL LINE [J].
GRASSMANN, R ;
FLECKENSTEIN, B .
JOURNAL OF VIROLOGY, 1989, 63 (04) :1818-1821
[10]   Herpesvirus saimiri-based gene delivery vectors [J].
Griffiths, RA ;
Boyne, JA ;
Whitehouse, A .
CURRENT GENE THERAPY, 2006, 6 (01) :1-15